Platelet signalling networks: Pathway perturbation demonstrates differential sensitivity of ADP secretion and fibrinogen binding

Platelets

Volumn 23, Issue 1, 2012, Pages 17-25

  Lombardi, Federica ^a,b   De Chaumont, Ciarn ^a   Shields, Denis C ^b   Moran, Niamh ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

ADP secretion; GpIIb IIIa antagonist; Integrin IIb 3; platelet; signalling

Indexed keywords

2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ALPHA2 INTEGRIN; BETA3 INTEGRIN; FIBRINOGEN; MRS 2395; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; THROMBOXANE A2; TIROFIBAN; UNCLASSIFIED DRUG; WORTMANNIN;

ARTICLE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; THROMBOCYTE;

ADENOSINE DIPHOSPHATE; BLOOD PLATELETS; FEMALE; FIBRINOGEN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MODELS, BIOLOGICAL; PHOSPHATIDYLINOSITOL 3-KINASES; PLATELET ADHESIVENESS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN-TYROSINE KINASES; RECEPTORS, PURINERGIC P2Y; RECEPTORS, PURINERGIC P2Y12; SIGNAL TRANSDUCTION;

EID: 83155167577     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2011.594190     Document Type: Article

References (50)

1. Savage B, Cattaneo M, Ruggeri ZM. Mechanisms of platelet aggregation. Curr Opin Hematol 2001;8(5):270-276. (Pubitemid 32826497)
2. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: The platelet paradigm. Blood 1998;91(8):2645-2657. (Pubitemid 28227512)
3. Wagner C, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996;88(3):907-914. (Pubitemid 26333313)
4. Moran N, Morateck PA, Deering A, Ryan M, Montgomery RR, Fitzgerald DJ, Kenny D. Surface expression of glycoprotein ib alpha is dependent on glycoprotein ib beta: Evidence from a novel mutation causing Bernard-Soulier syndrome. Blood 2000;96(2):532-539. (Pubitemid 30463372)
5. Nachman RL, Leung LL. Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen. J Clin Invest 1982;69(2):263-269. (Pubitemid 12177603)
6. Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: The end game. Nat Rev Mol Cell Biol 2010;11(4):288-300.
7. Vinogradova O, Velyvis A, Velyviene A, Hu B, Haas T, Plow E, Qin J. A structural mechanism of integrin alpha(IIb)beta(3) inside-out activation as regulated by its cytoplasmic face. Cell 2002;110(5):587-597. (Pubitemid 35247839)
8. Hynes RO. Integrins: Bidirectional, allosteric signaling machines. Cell 2002;110(6):673-687. (Pubitemid 35283958)
9. Cattaneo M, Canciani MT, Lecchi A, Kinlough- Rathbone RL, Packham MA, Mannucci PM, Mustard JF. Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. Blood 1990;75(5):1081-1086. (Pubitemid 20086813)
10. FitzGerald GA. Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991;68(7):11B-15B.
11. Storey RF, Newby LJ, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001;12(7):443-447. (Pubitemid 33097240)
12. Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP. Nucleotide receptor signaling in platelets. J Thromb Haemost 2006;4(11):2317-2326. (Pubitemid 44575423)
13. Samuelsson B, Goldyne M, Granstrom E, Hamberg M, Hammarstrom S, Malmsten C. Prostaglandins and thromboxanes. Annu Rev Biochem 1978;47:997-1029.
14. Santoro SA. Identification of a 160,000 dalton platelet membrane protein that mediates the initial divalent cationdependent adhesion of platelets to collagen. Cell 1986;46(6):913-920. (Pubitemid 16027939)
15. Nieswandt B, Watson SP. Platelet-collagen interaction: Is GPVI the central receptor? Blood 2003;102(2):449-461. (Pubitemid 36841960)
16. Clemetson JM, Polgar J, Magnenat E, Wells TN, Clemetson KJ. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors. J Biol Chem 1999;274(41):29019-29024.
17. Gibbins JM, Okuma M, Farndale R, Barnes M, Watson SP. Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gammachain. FEBS Lett 1997;413(2):255-259. (Pubitemid 27353279)
18. Poole A, Gibbins JM, Turner M, van Vugt MJ, van de Winkel JG, Saito T, Tybulewicz VL, Watson SP. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 1997;16(9):2333-23341.
19. Asselin J, Gibbins M, Achison M, Lee YH, Morton LF, Farndale RW, Barnes MJ, Watson SP. A collagen-like peptide stimulates tyrosine phosphorylation of syk and phospholipase C gamma2 in platelets independent of the integrin alpha2- beta1. Blood 1997;89(4):1235-1242. (Pubitemid 27079987)
20. Dangelmaier CA, Quinter PG, Jin J, Tsygankov AY, Kunapuli SP, Daniel JL. Rapid ubiquitination of Syk following GPVI activation in platelets. Blood 2005;105(10):3918-3924. (Pubitemid 40656137)
21. Pasquet JM, Bobe R, Gross B, Gratacap MP, Tomlinson MG, Payrastre B, Watson SP. A collagen-related peptide regulates phospholipase Cgamma2 via phosphatidylinositol 3-kinase in human platelets. Biochem J 1999;342 (Pt 1):171-177. (Pubitemid 29410863)
22. Gibbins JM, Briddon S, Shutes A, van Vugt MJ, van de Winkel JG, Saito T, Watson SP. The p85 subunit of phosphatidylinositol 3-kinase associates with the Fc receptor gamma-chain and linker for activitor of T cells (LAT) in platelets stimulated by collagen and convulxin. J Biol Chem 1998;273(51):34437-3443.
23. Knight CG, Morton LF, Onley DJ, Peachey AR, Ichinohe T, Okuma M, Farndale RW, Barnes MJ. Collagen-platelet interaction: Gly-Pro-Hyp is uniquely specific for platelet Gp VI and mediates platelet activation by collagen. Cardiovasc Res 1999;41(2):450-457. (Pubitemid 29087341)
24. Michelson AD. Platelets, 2nd edn. Burlington, MA, London: Academic Press; 2007. p xlii, 1343 p.
25. Watson SP, Auger JM, McCarty OJ, Pearce AC. GPVI and integrin alphaIIb beta3 signaling in platelets. J Thromb Haemost 2005;3 (8):1752-1762. (Pubitemid 41716562)
26. Edwards RJ, Moran N, Devocelle M, Kiernan A, Meade G, Signac W, Foy M, Park SD, Dunne E, Kenny D, et al. Bioinformatic discovery of novel bioactive peptides. Nat Chem Biol 2007;3(2):108-112. (Pubitemid 46134997)
27. Sun B, Tandon NN, Yamamoto N, Yoshitake M, Kambayashi J. Luminometric assay of platelet activation in 96-well microplate. Biotechniques 2001;31(5):1174, 1176, 1178 passim.
28. Moran N, Kiernan A, Dunne E, Edwards RJ, Shields DC, Kenny D. Monitoring modulators of platelet aggregation in a microtiter plate assay. Anal Biochem 2006;357 (1):77-84. (Pubitemid 44331163)
29. Hisamichi H, Naito R, Toyoshima A, Kawano N, Ichikawa A, Orita A, Orita M, Hamada N, Takeuchi M, Ohta M, et al. Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives. Bioorg Med Chem 2005;13(16):4936-4951. (Pubitemid 40943518)
30. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, Pirola L, Vanhaesebroeck B, Waterfield MD, Panayotou G. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 1996;16(4):1722-1733. (Pubitemid 26095645)
31. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231(25):232-235.
32. Ogletree ML, Harris DN, Greenberg R, Haslanger MF, Nakane M. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther 1985;234(2):435-441. (Pubitemid 15241865)
33. Boyer JL, Mohanram A, Camaioni E, Jacobson KA, Harden TK. Competitive and selective antagonism of P2Y1 receptors by N6-methyl 20-deoxyadenosine 30,50-bisphosphate. Br J Pharmacol 1998;124(1):1-3. (Pubitemid 28210035)
34. Xu B, Stephens A, Kirschenheuter G, Greslin AF, Cheng X, Sennelo J, Cattaneo M, Zighetti ML, Chen A, Kim SA, et al. Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: Phosphate substitution leads to multiple pathways of inhibition of platelet aggregation. J Med Chem 2002;45(26):5694-5709. (Pubitemid 35453762)
35. Nakanishi S, Kakita S, Takahashi I, Kawahara K, Tsukuda E, Sano T, Yamada K, Yoshida M, Kase H, Matsuda Y, et al. Wortmannin, a microbial product inhibitor of myosin light chain kinase. J Biol Chem 1992;267(4):2157-2163.
36. Cross MJ, Stewart A, Hodgkin MN, Kerr DJ, Wakelam MJ. Wortmannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in Swiss 3T3 cells. Wortmannin is not a specific inhibitor of phosphatidylinositol 3-kinase. J Biol Chem 1995;270(43):25352-25355.
37. Egbertson MS, Chang CT, Duggan ME, Gould RJ, Halczenko W, Hartman GD, Laswell WL, Lynch Jr JJ, Lynch RJ, Manno PD, et al. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J Med Chem 1994;37(16):2537-2551. (Pubitemid 24276781)
38. Xiao T, Takagi J, Coller BS, Wang JH, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004;432(7013):59-67. (Pubitemid 39490825)
39. Watanabe N, Nakajima H, Suzuki H, Oda A, Matsubara Y, Moroi M, Terauchi Y, Kadowaki T, Koyasu S, Ikeda Y, et al. Functional phenotype of phosphoinositide 3-kinase p85alphanull platelets characterized by an impaired response to GP VI stimulation. Blood 2003;102(2):541-548. (Pubitemid 36841973)
40. Canobbio I, Stefanini L, Cipolla L, Ciraolo E, Gruppi C, Balduini C, Hirsch E, Torti M. Genetic evidence for a predominant role of PI3Kbeta catalytic activity in ITAMand integrin-mediated signaling in platelets. Blood 2009;114(10):2193-2196.
41. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: Insights from gene-targeted mice. Trends Biochem Sci 2005;30(4):194-204. (Pubitemid 40463309)
42. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010;11(5):329-341.
43. Peter K, Schwarz M, Ylanne J, Kohler B, Moser M, Nordt T, Salbach P, Kubler W, Bode C. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 1998;92(9):3240-3249. (Pubitemid 28492331)
44. Cox D, Smith R, Quinn M, Theroux P, Crean P, Fitzgerald DJ. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000;36(5):1514- 1519.
45. Bassler N, Loeffler C, Mangin P, Yuan Y, Schwarz M, Hagemeyer CE, Eisenhardt SU, Ahrens I, Bode C, Jackson SP, et al. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/ IIIa) antagonists. Arterioscler Thromb Vasc Biol 2007;27(3):e9-15.
46. Jones ML, Harper MT, Aitken EW, Williams CM, Poole AW. RGD-ligand mimetic antagonists of integrin alphaIIbbeta3 paradoxically enhance GPVI-induced human platelet activation. J Thromb Haemost 2010;8(3):567-576.
47. Newby LK, Califf RM, White HD, Harrington RA, Van de Werf F, Granger CB, Simes RJ, Hasselblad V, Armstrong PW. The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am J Med 2002;112(8):647-658. (Pubitemid 34597166)
48. Nieswandt B, Bergmeier W, Eckly A, Schulte V, Ohlmann P, Cazenave JP, Zirngibl H, Offermanns S, Gachet C. Evidence for cross-talk between glycoprotein VI and Gi-coupled receptors during collagen-induced platelet aggregation. Blood 2001;97(12):3829-3835.
49. Larson MK, Chen H, Kahn ML, Taylor AM, Fabre JE, Mortensen RM, Conley PB, Parise LV. Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets. Blood 2003;101(4):1409-1415. (Pubitemid 36182513)
50. Jin J, Quinton TM, Zhang J, Rittenhouse SE, Kunapuli SP. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors. Blood 2002;99(1):193-198.